Financials · BTMD

Biote Corp. (BTMD) financials

For the twelve months ended Sep 30, 2026, Biote Corp. reported $178.91M of revenue and -$2.39M of net income.

Revenue, TTM
$178.91M
Revenue growth, YoY
-8.6%
Net income, TTM
-$2.39M
Net margin
-1.3%
Free cash flow, TTM
$7.41M
EPS, diluted, TTM
-$0.11
Cash
$8.85M
Total debt
$120.07M
P/S
0.22
Market cap
$39.9M
Annual revenue$192.22M
FY2021FY2025
Annual net income$27.05M
FY2021FY2025
Annual free cash flow$30.18M
FY2021FY2025

BTMD revenue and earnings growth

BTMD revenueQ3 2026$43.33M

Quarter YoY
-9.6%
QoQ
-2.0%
FY YoY
-2.5%

BTMD revenue was $43.33M in fiscal Q3 2026 (ended Sep 30, 2026), down 9.6% from a year earlier and down 2.0% from the prior quarter. For the full fiscal 2025 it was $192.22M, down 2.5% from fiscal 2024. It rose in 3 of the last 4 fiscal years.

BTMD net incomeQ3 2026$407.0K

Quarter YoY
-95.0%
FY YoY
+756.7%

BTMD net income was $407.0K in fiscal Q3 2026 (ended Sep 30, 2026), down 95.0% from a year earlier. For the full fiscal 2025 it was $27.05M, up 756.7% from fiscal 2024.

BTMD EPSQ3 2026$0.01

Quarter YoY
-95.5%
FY YoY
+722.2%

BTMD diluted EPS was $0.01 in fiscal Q3 2026 (ended Sep 30, 2026), down 95.5% from a year earlier. For the full fiscal 2025 it was $0.74, up 722.2% from fiscal 2024.

BTMD free cash flowQ3 2026$1.11M

Quarter YoY
-91.8%
FY YoY
-22.2%

BTMD free cash flow was $1.11M in fiscal Q3 2026 (ended Sep 30, 2026), down 91.8% from a year earlier. For the full fiscal 2025 it was $30.18M, down 22.2% from fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Revenue$192.22M$197.19M$185.36M$164.96M$139.40M
Selling, general and admin$101.81M$107.45M$98.83M$171.10M$49.05M
Operating income$35.55M$31.61M$28.66M-$60.72M$34.56M
Pre-tax income$37.58M$1.02M-$123.0K$1.71M$32.91M
Income tax$5.99M$970.0K$2.68M$388.0K$286.0K
Net income$27.05M$3.16M$3.32M-$969.0K$32.62M
EPS, basic$0.86$0.09$0.13-$0.12-
EPS, diluted$0.74$0.09$0.13-$0.12-
Diluted shares36.7M34.3M25.7M8.1M-

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Cash and equivalents$24.12M$39.34M$89.00M$79.23M$26.77M
Receivables$6.87M$7.63M$6.81M$6.95M$5.23M
Inventory$19.06M$14.85M$17.31M$11.18M$9.62M
Current assets$54.67M$68.13M$122.34M$101.18M$47.09M
Goodwill$5.83M$5.83M---
Total assets$107.61M$122.37M$155.29M$111.64M$54.33M
Current liabilities$44.99M$51.51M$22.21M$18.77M$17.31M
Short-term debt$6.25M$6.25M$6.25M$6.25M$5.00M
Long-term debt$95.78M$101.20M$106.63M$112.09M$31.96M
Total debt$102.03M$107.45M$112.88M$118.34M$36.96M
Total liabilities$158.01M$224.57M$191.84M$169.92M$50.20M
Shareholders' equity-$58.54M-$102.20M-$36.55M-$58.27M$4.13M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Operating cash flow$35.19M$45.24M$26.88M-$9.16M$33.72M
Capital expenditures$5.01M$6.43M$359.0K$333.0K$1.45M
Free cash flow$30.18M$38.81M$26.52M-$9.49M$32.27M
Investing cash flow-$6.86M-$18.80M-$2.71M-$1.84M-$3.81M
Financing cash flow-$43.55M-$76.08M-$14.38M$63.46M-$20.34M
Dividends paid$1.73M$4.74M$8.69M$12.89M$11.40M
Share repurchases$3.37M$5.60M---
Stock-based compensation$8.92M$8.73M$9.06M$82.18M-
Depreciation and amortization$3.67M$3.57M$2.99M$2.20M$1.40M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Revenue growth, YoY-2.5%6.4%12.4%18.3%-
Net income growth, YoY756.7%-4.8%---
EPS growth, YoY722.2%-30.8%---
Operating margin18.5%16.0%15.5%-36.8%24.8%
Net margin14.1%1.6%1.8%-0.6%23.4%
Free cash flow margin15.7%19.7%14.3%-5.8%23.2%
Return on equity----790.8%
Return on assets25.1%2.6%2.1%-0.9%60.0%
Current ratio1.221.325.515.392.72
Debt to equity----8.96

Source: XBRL data Biote Corp. files with the SEC, latest filing dated Nov 9, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

BTMD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
BTMD$178.91M-8.6%-$2.39M-1.3%$39.9M
PM$43.14B+7.9%$10.71B24.8%$301.01B
BTI£25.61B-1.0%£7.76B30.3%$129.81B
MO$23.52B+0.5%$8.12B34.5%$126.11B
DFTX---$337.48M-$4.76B
RGC---$11.70M-$2.79B
TRLV$1.08B-9.1%-$445.60M-41.2%$2.12B
RLXCN¥3.96B+44.0%CN¥921.87M23.3%$1.94B
CRON$271.85M+54.3%$63.36M23.3%$1.30B

BTMD FAQ

8 questions
  • What is BTMD revenue?
    Biote Corp. (BTMD) reported $178.91M of revenue for the twelve months ended Sep 30, 2026. That is down 8.6% from the year before. Revenue for fiscal 2025 was $192.22M.
  • Is BTMD profitable?
    No. Biote Corp. reported a net loss of $2.39M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does BTMD have?
    Biote Corp. reported $8.85M in cash and cash equivalents and $120.07M of debt on its most recent balance sheet in SEC filings.
  • How fast is BTMD revenue growing?
    Biote Corp.'s revenue changed -2.5% in fiscal 2025, to $192.22M.
  • What is BTMD free cash flow?
    Biote Corp. generated $7.41M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $13.98M less capital expenditures.
  • What is BTMD earnings per share?
    Diluted earnings per share were -$0.11 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did BTMD last report financial results?
    The latest statements here come from Biote Corp.'s 10-Q filed on Nov 9, 2026, covering the period ended Sep 30, 2026.
  • Where does this BTMD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Biote Corp. files with the SEC. It is provided for information only and is not investment advice.